Preclinical Products Overview

Developing new and innovative products to help treat unmet medical needs is key to preclinical development at CPSI. At the forefront of innovation, the Company continues to develop new technologies with a broad range of applications. Currently, CPSI follows a risk-balanced model under which it acquires technologies from academia and other sources, conceives products from those technologies and takes those products through clinical development.

Please see below for a brief list of compounds and targets currently in preclinical development.

• MIF Inhibitors – Arthritis, Septic Shock, Cancer, Glomerulonephritis, Diabetes, Multiple Sclerosis and Colitis
• iPFK-2 Inhibitors – Various Cancers
• Next™ Nuclear Importation Inhibitors – HIV